Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor‑κB activity in human oral cancer cells

Tamatani,Tetsuya; Takamaru,Natsumi; Hara,Kanae; Kinouchi,Makoto; Kuribayashi,Nobuyuki; Ohe,Go; Uchida,Daisuke; Fujisawa,Kenji; Nagai,Hirokazu; Miyamoto,Youji

doi:10.3892/ijo.2013.1786

Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor‑κB activity in human oral cancer cells

Authors:
- Tetsuya Tamatani
- Natsumi Takamaru
- Kanae Hara
- Makoto Kinouchi
- Nobuyuki Kuribayashi
- Go Ohe
- Daisuke Uchida
- Kenji Fujisawa
- Hirokazu Nagai
- Youji Miyamoto
View Affiliations

Affiliations: Department of Oral Surgery, Subdivision of Molecular Oral Medicine, Division of Integrated Sciences of Translational Research, Institute of Health Biosciences, the University of Tokushima Graduate School, Tokushima 770-8504, Japan
Published online on: January 22, 2013 https://doi.org/10.3892/ijo.2013.1786
Pages: 935-944

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral cancer cells have a significantly augmented nuclear factor-κB (NF-κB) activity and the inhibition of this activity suppresses tumor growth. Bortezomib is a proteasome inhibitor and a drug used for molecular-targeted therapy (targets NF-κB). In this study, we investigated whether bortezomib would be effective as an inhibitor of proliferation and a radiosensitizer for the treatment of oral cancer. We demonstrate that bortezomib inhibits NF-κB activity and cell proliferation. The combined treatment with bortezomib and radiation (RT) suppressed NF-κB activity and cell growth in vitro and in vivo compared with RT treatment alone. To investigate the mechanisms by which bortezomib suppresses tumor growth, the expression of signaling molecules downstream of NF-κB were examined by ELISA. The combined treatment significantly inhibited the radiation‑induced production of angiogenic factors and decreased the number of blood vessels in the tumor tissues. Although the expression of anti‑apoptotic proteins was upregulated by RT, bortezomib downregulated the RT-induced expression of these proteins. Moreover, the expression of cleaved poly(ADP‑ribose) polymerase in vitro and in vivo was enhanced by bortezomib, indicating that bortezomib inhibits tumor growth by inducing apoptosis. This study clearly demonstrates that bortezomib significantly inhibits tumor growth and that the combined treatment with bortezomib and RT results in a significant inhibition of tumor growth. The mechanisms underlying the inhibition of tumor growth by bortezomib include the suppression of angiogenesis and the induction of apoptosis. A novel molecular targeting therapy including bortezomib may be effective in the treatment of oral cancer by suppressing NF-κB activity.

View Figures

View References

1	Sen R and Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:705–716. 1986. View Article : Google Scholar : PubMed/NCBI
2	Baeuerle PA and Baltimore D: NF-kappa B: ten years after. Cell. 87:13–20. 1996.PubMed/NCBI
3	Yamamoto Y and Gaynor RB: IκB kinases: key regulators of the NF-κB pathway. Trends Biochem Sci. 29:72–79. 2004.
4	Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-κB. Science. 274:787–789. 1996.
5	Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S and Baeuerle PA: Phosphorylation of human IkappaB-alpha on serines 32 and 36 controls Ikappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 14:2876–2883. 1995.
6	Karashima T, Sweeney P, Kamat A, et al: Nuclear factor-κB mediates angiogenesis and metastasis of human bladder cancer through regulation of interleukin-8. Clin Cancer Res. 9:2786–2797. 2003.
7	Dhawan P, Singh AB, Ellis DL and Richmond A: Constitutive activation of Akt/Protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res. 62:7335–7342. 2002.PubMed/NCBI
8	Sato H and Seiki M: Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene. 8:395–405. 1993.PubMed/NCBI
9	Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 281:1680–1683. 1998.
10	Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med. 5:412–417. 1999.PubMed/NCBI
11	Hideshima T, Chauhan D, Richardson P, et al: NF-κB as a therapeutic target in multiple myeloma. J Biol Chem. 277:16639–16647. 2002.
12	Denlinger CE, Rundall BK and Jones DR: Modulation of anti-apoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-κB. Semin Thorac Cardiovasc Surg. 16:28–39. 2004.PubMed/NCBI
13	Smith CW, Chen Z, Dong G, et al: The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1α, IL-6, GM-CSF and KC. Clin Exp Metastasis. 16:655–664. 1998.PubMed/NCBI
14	Tamatani T, Azuma M, Aota K, Yamashita T, Bando T and Sato M: Enhanced IκB kinase activity is responsible for the augmented activity of NF-κB in human head and neck carcinoma cells. Cancer Lett. 171:165–172. 2001.
15	Tamatani T, Azuma M, Ashida Y, et al: Enhanced radiosensitization and chemosensitization in NF-κB suppressed human oral cancer cells via the inhibition of γ-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer. 108:912–921. 2004.
16	Visconti R, Cerutti J, Battista S, et al: Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF-κB p65 protein expression. Oncogene. 15:1987–1994. 1997.PubMed/NCBI
17	Sartore-Bianchi FA, Gasparri F, Galvani A, et al: Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res. 13:5942–5951. 2007.
18	Canfield SE, Zhu K, Williams SA and McConkey DJ: Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther. 5:2043–2050. 2006. View Article : Google Scholar : PubMed/NCBI
19	Bazzaro M, Lee MK, Zoso A, et al: Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 66:3754–3763. 2006. View Article : Google Scholar : PubMed/NCBI
20	An J, Sun YP, Adams J, Fisher M, Belldegrun A and Rettig MB: Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) α and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res. 9:4537–4545. 2003.
21	Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 11:7490–7498. 2005.
22	Olivier S, Robe P and Bours V: Can NF-κB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol. 72:1054–1068. 2006.
23	Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C and Krönke M: NF-κB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood. 109:3982–3988. 2007.
24	Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59:2615–2622. 1999.PubMed/NCBI
25	Duffey DC, Chen Z, Dong G, et al: Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression and tumor growth in vivo. Cancer Res. 59:3468–3474. 1999.
26	Tomita T, Takeuchi E, Tomita N, et al: Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 42:2532–2542. 1999.PubMed/NCBI
27	Kim IA, Bae SS, Fernandes A, et al: Selective inhibition of Ras, phosphoinositide 3 kinase and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 65:7902–7910. 2005.PubMed/NCBI
28	Matsumoto G, Namekawa J, Muta M, et al: Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 11:1287–1293. 2005.
29	Messersmith WA, Baker SD, Lassiter L, et al: Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 12:1270–1275. 2006. View Article : Google Scholar : PubMed/NCBI
30	Cataldi A, Rapino M, Centurione L, et al: NF-κB activation plays an antiapoptotic role in human leukemic K562 cells exposed to ionizing radiation. J Cell Biochem. 89:956–963. 2003.
31	Loercher A, Lee TL, Ricker JL, et al: Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res. 64:6511–6523. 2004.
32	Van Waes C, Chang AA, Lebowitz PF, et al: Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 63:1400–1412. 2005.
33	Nakagawa K, Tamura T, Negoro S, et al: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 14:922–930. 2003.
34	Tan C and Waldmann TA: Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 62:1083–1086. 2002.PubMed/NCBI
35	Scaife CL, Kuang J, Wills JC, et al: Nuclear factor κB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res. 62:6870–6878. 2002.
36	LeBlanc R, Catley LP, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:4996–5000. 2002.PubMed/NCBI
37	Amiri KI, Horton LW, LaFleur BJ, Sosman JA and Richmond A: Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 64:4912–4918. 2004. View Article : Google Scholar
38	Rahman KM and Sarkar FH: Inhibition of nuclear translocation of nuclear factor-κB contributes to 3,3′-diindolyl-methane-induced apoptosis in breast cancer cells. Cancer Res. 65:364–371. 2005.
39	Huang S, Robinson JB, Deguzman A, et al: Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60:5334–5339. 2000.
40	Arlt A, Vorndamm J, Müerköster S, et al: Autocrine production of interleukin 1β confers constitutive nuclear factor κB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 62:910–916. 2002.
41	Yang J and Richmond A: Constitutive IκB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Res. 61:4901–4909. 2001.
42	Kothny-Wilkes G, Kulms D, Luger TA, et al: Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand- and CD95-induced apoptosis but not from ultraviolet radiation-induced apoptosis. J Biol Chem. 274:28916–28921. 1999. View Article : Google Scholar
43	Vale T, Ngo TT, White MA and Lipsky PE: Raf-induced transformation requires an interleukin 1 autocrine loop. Cancer Res. 61:602–607. 2001.PubMed/NCBI
44	Huang TT, Wuerzberqer-Davis SM, Wu ZH, et al: Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell. 115:565–576. 2003.PubMed/NCBI
45	Mabb AM, Wuerzberqer-Davis SM and Miyamoto S: PIASy mediates NEMO sumoylation and NF-κB activation in response to genotoxic stress. Nat Cell Biol. 8:986–993. 2006.PubMed/NCBI
46	Janssens S and Tschopp J: Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ. 13:773–784. 2006.
47	Munshi A, Kurland JF, Nishikawa T, et al: Inhibition of constitutively activated nuclear factor-κB radiosensitizes human melanoma cells. Mol Cancer Ther. 3:985–992. 2004.
48	Shumway SD and Miyamoto S: A mechanistic insight into a proteasome-independent constitutive inhibitor κBα (IκBα) degradation and nuclear factor κB (NF-κB) activation pathway in WEHI-231 B-cells. Biochem J. 380:173–180. 2004.PubMed/NCBI
49	Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:3374–3378. 1999.PubMed/NCBI
50	De Larco JE, Wuertz BR, Manivel JC and Furcht LT: Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res. 61:2857–2861. 2001.PubMed/NCBI
51	Conze D, Weiss L, Regen PS, et al: Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 61:8851–8858. 2001.PubMed/NCBI
52	Tang G, Minemoto Y, Dibling B, et al: Inhibition of JNK activation through NF-κB target genes. Nature. 414:313–317. 2001.
53	Yu C, Friday BB, Lai JP, Yang L, et al: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 5:2378–2387. 2006. View Article : Google Scholar
54	Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G and Wolf D: Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun. 361:549–554. 2007. View Article : Google Scholar : PubMed/NCBI